An FDA advisory committee meets July 23–24 to decide whether seven peptides — including BPC-157 and TB-500 — belong on the list pharmacies may legally compound from. It is the most consequential peptide-policy moment in years, and the most misunderstood. The vote is about legal supply, not scientific proof.
On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee will take up a question that has consumed the longevity and wellness world for most of the year: whether a group of widely discussed peptides should be eligible for legal compounding by licensed pharmacies. The agenda is specific. On the first day the committee will review BPC-157, KPV, TB-500, and MOTS-C; on the second, delta sleep-inducing peptide (Emideltide), Semax, and Epitalon — each considered for inclusion on the 503A bulk drug substances list.
This is the culmination of a reversal that began earlier in the year, when peptides the FDA had restricted in 2023 started moving back off its most restrictive list. But the framing in much of the coverage has been misleading, and the distinction is worth stating plainly.
The committee is not deciding whether these peptides are FDA-approved drugs. It is deciding whether licensed compounding pharmacies may legally prepare them for individual patients under a prescription. Those are different questions with different evidence bars. Drug approval requires large controlled human trials; compounding eligibility does not. A peptide can become eligible for compounding while still having very little human data behind it — and most of these do.
The committee’s recommendations are also advisory rather than binding. The FDA retains final authority over what lands on the 503A list. The panel’s vote will shape the outcome and signal the agency’s direction, but it is a step in a process, not a final verdict.
"Eligible for compounding" is a statement about legal supply. It is not a statement that a peptide is safe, effective, or endorsed by the FDA. If a clinic or vendor cites this decision as proof that a peptide "works," that is a category error — the regulatory question and the scientific question are unrelated.
The 2023 restrictions did not eliminate demand for these compounds; they pushed much of it into the unregulated "research chemical" gray market, where purity, dose, and sterility are nobody’s responsibility. A return to legal compounding could, at the margin, improve safety for people who are going to use these peptides regardless — by routing them through licensed pharmacies that perform identity, potency, and sterility testing under physician oversight. That is a real potential benefit, but it is a benefit about quality control, not about proven efficacy.
It is also not an all-or-nothing outcome. The committee can recommend some compounds and not others, or clear a peptide only for a narrow, specified use. The FDA has previously flagged impurity and characterization concerns for several of these substances, so manufacturing quality — not just biology — will be part of the discussion.
The immediate question is which of the seven, if any, the committee recommends for the 503A list, and with what restrictions. The deeper question is whether this regulatory thaw prompts anyone to fund the rigorous human trials these peptides have always lacked. Legal access and scientific evidence are separate problems; solving the first does nothing to solve the second. We have published a full, evidence-based explainer of the reclassification and what it does and does not mean, and we will report the committee’s recommendations here once they are public.